AR and posterior cortical atrophy: Similarly, targeting surfaces of the AR distinct from the LBP (AF1, AF2, BF3, DBD) while also posing significant challenges, offer the potential for developing “selective androgen receptor modulators” and novel inhibitors to overcome drug resistance that arises in advanced and metastatic PCa and for reducing side-effects.